
AVEO PHARMA LIMITED

UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2022

AVEO PHARMA LIMITED
REGISTERED NUMBER: 06456614

BALANCE SHEET
AS AT 31 DECEMBER 2022

	Note	2022 £	2021 £
Current assets			
Debtors: amounts falling due within one year	3	646,113	646,113
Total assets less current liabilities		646,113	646,113
Net assets		646,113	646,113
Capital and reserves			
Called up share capital		2	2
Other reserves	4	5,076,155	5,076,155
Profit and loss account	4	(4,430,044)	(4,430,044)
		646,113	646,113

For the year ended 31 December 2022 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

Members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

.....
Danielle Holland
Director

Date: 21 September 2023

The notes on pages 2 to 3 form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

1. General information

Aveo Pharma Limited (the Company) is a company incorporated in the United Kingdom under the Companies Act.

The Company is a private company limited by shares and is registered in England and Wales. The address of the Company's registered office is 5th Floor Halo, Counterslip, Bristol, BS1 6AJ.

The Company's functional and presentational currency is pounds sterling (GBP) and the financial statements are rounded to the nearest pound (£).

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

3. Debtors

	2022 £	2021 £
Amounts owed by group undertakings	646,113	646,113
	<u>646,113</u>	<u>646,113</u>

4. Reserves

Other reserves

Other reserves represents the amount relating to additional paid in capital which exceeds the nominal value of the shares and represents the capital contribution.

Profit and loss account

Profit and loss account represents the cumulative profits or losses net of dividends paid and other adjustments.

5. Related party transactions

The ultimate parent company is Aveo Pharmaceuticals Inc. (registered and incorporated in the United States of America). The largest and smallest group in which the results of the company are consolidated is that headed by Aveo Pharmaceuticals Inc. The consolidated accounts of this company are available to the public and may be obtained from www.aveooncology.com.

AVEO PHARMA LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

6. Post balance sheet events

AVEO Pharmaceuticals Inc., the parent company of Aveo Pharma Ltd., was acquired by LG Chem Ltd. in January of 2023.

7. Controlling party

The directors of the company do not consider there to be an ultimate controlling party.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.